When was Oligon founded?

Oligon was founded in 2021 and raised its 1st funding round 4 years after it was founded.

Where is Oligon located?

Oligon is headquartered in Scottsdale, United States.

How many employees does Oligon have?

As of Jun 30, 2026, the latest employee count at Oligon is 7.

Is Oligon a funded company?

Oligon is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Sep 2025.

When was the latest funding round of Oligon?

Oligon's latest funding was a $***** Series B round on Sep 2025, with participation from 3 investors.

Where does Oligon rank among its competitors?

Oligon ranks 1619th amongst 3313 active competitors, of which 1130 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Oligon?

Oligon's top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Oligon - 2026 Company Profile, Funding & Competitors

Oligon is a series B company based in Scottsdale (United States), founded in 2021. It operates as a Developer of gene therapies for the treatment of cancer and other diseases. Oligon has raised $14M in funding. The company has 3313 active competitors, including 1130 funded and 791 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Sana Biotechnology.

Company Details

Developer of gene therapies for the treatment of cancer and other diseases. It offers the SeekR RNA therapeutic platform which provides SiRNA-based single multitargeting agents for treating complex diseases.

Website: www.oligon.com/en
Social
Email ID: *****@oligon.com

Key Metrics

Founded Year

2021

Location

Scottsdale, United States

Stage

Series B

Total Funding

$14M in 1 round

Latest Funding Round

Series B, Sep 2025, $*****

Investors

CTI Life Sciences Fund & 2 more

Ranked

1619^th among 3313 active competitors

Employee Count

7 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3034 more

View Oligon's full profile

Oligon has raised a total funding of $14M over 1 round. Its latest funding round was a Series B round on Sep 2025 for $*****. 3 investors participated in its latest round. Oligon has 3 institutional investors.

Here is the list of recent funding rounds of Oligon:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 2025	2745102	Series B	8210247	9471302	7769826	9809712

Access funding benchmarks and valuations. Sign up today!

View details of Oligon's funding rounds and investors

Oligon's employee count trend

Oligon has 7 employees as of Jun 26. Here is Oligon's employee count trend over the years:

Uncover Oligon's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oligon include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Oligon, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
1619th	Oligon 2021, Scottsdale (United States), Series B	Developer of gene therapies for the treatment of cancer and other diseases	$14M	CTI Life Sciences Fund, Invest Quebec & 1 others	32/100